In prostate cancer, the loss-of-function mutation of SPOP (an E3 ubiquitin ligase of Brd4) has been shown to confer resistance to BET inhibitors by impairing ubiquitination-mediated Brd4 degradation [157,158]. The gene discussed is SPOP; the disease is prostate cancer.